Octreotide

Octreotide has no established direct tubular or glomerular toxicity. Any renal relevance is indirect and pharmacokinetic: the peptide is partly renally eliminated, so clearance falls and exposure rises in significant renal impairment (uremia prolongs disposal of somatostatin-suppressible hormones, illustrating the kidney's role in clearance of this axis). Conversely, experimental data suggest octreotide can be renoprotective via antioxidant effects, improving renal catalase levels and glomerular histology in an adriamycin nephrotic model. Rare electrolyte effects relate to its broad antisecretory hormonal action rather than to structural kidney injury.

Typically none referable to the kidney. When relevant, manifestations are mild and indirect: occasional electrolyte shifts, or — in the context of underlying hormone-secreting tumors — paraneoplastic SIADH/hyponatremia for which octreotide has been explored as adjunctive tumor-directed control rather than as a cause. In severe renal impairment, drug accumulation rather than nephrotoxicity is the concern.

Not applicable for intrinsic injury; pharmacokinetic accumulation in renal failure is gradual.

Synthetic octapeptide analog of somatostatin that binds somatostatin receptors (predominantly SSTR2/SSTR5) on neuroendocrine tumor cells, inhibiting secretion of growth hormone, glucagon, insulin, and a range of gut hormones, and exerting antiproliferative/antisecretory effects; used to control hormonal hypersecretion syndromes and, with the long-acting formulation, for tumor stabilization.

No renal-specific management is required in most patients. In severe renal impairment, consider that systemic exposure is increased and titrate/monitor accordingly. Manage any electrolyte abnormalities supportively and treat the underlying tumor.